Stephen Grabelsky, MD
Medical Oncology · Delray Beach, FLNPI 1366490781
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (43.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 38 manufacturers reported payments, led by Tesaro, Inc. at 56.8% of the total. Reporting peaked in 2019 at $6,887 and has fallen 91.6% since, to $581 in 2025. That places this record below the midpoint for medical oncology clinicians in FL, where the typical reported total is $8,890.
Across 207 payments — averaging $45.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tesaro, Inc.$5K
- Beigene USA, Inc.$544
- Johnson & Johnson$483
- Pfizer$323
- Astellas Pharma US Inc$312
- Novartis$291
- plus $2K from 32 others
Across 22 payments — averaging $10,497 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$205K
- Biontech SE$26K
What the payments were for
- Consulting fees$4,02543%
- Travel & lodging$1,53516%
- Food & beverage$3,58838%
- Education$2132%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tesaro, Inc. | 11 | $5,322 |
| Beigene USA, Inc. | 2 | $544 |
| Johnson & Johnson | 23 | $483 |
| Pfizer | 27 | $323 |
| Astellas Pharma US Inc | 8 | $312 |
| Novartis | 20 | $291 |
| E.r. Squibb & Sons, L.L.C. | 19 | $290 |
| Genentech USA, Inc. | 9 | $167 |
| AstraZeneca | 8 | $152 |
| Merck | 9 | $137 |
| AbbVie | 6 | $129 |
| Array Biopharma Inc | 4 | $101 |
| Seagen Inc. | 5 | $101 |
| GSK | 4 | $84 |
| Bristol Myers Squibb | 4 | $78 |
| Lilly USA, LLC | 4 | $71 |
| Eisai Inc. | 4 | $70 |
| Bayer | 3 | $61 |
| Exelixis Inc. | 3 | $60 |
| Sanofi | 3 | $58 |
| Aurobindo Pharma USA, Inc. | 4 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $51 |
| Mirati Therapeutics, Inc. | 2 | $49 |
| Amgen | 4 | $49 |
| Gilead(2 entities) | 2 | $47 |
| Ipsen Biopharmaceuticals, Inc | 2 | $43 |
| Deciphera Pharmaceuticals Inc. | 2 | $35 |
| AMAG Pharmaceuticals, Inc. | 2 | $27 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Taiho Oncology, Inc. | 1 | $20 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
| Kyowa Kirin, Inc. | 1 | $19 |
| Sun Pharmaceutical Industries Inc. | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Rigel Pharmaceuticals, Inc. | 1 | $17 |
| Dova Pharmaceuticals | 1 | $15 |
| Boehringer Ingelheim | 1 | $14 |
| Agios Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,361 in reported general payments places this provider in the 50th percentile of 507 medical oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TasignaNilotinib Hcl | 16 | $361,556 |
| Lenalidomide | 24 | $303,192 |
| OjjaaraMomelotinib Dihydrochloride | 11 | $271,210 |
| BrukinsaZanubrutinib | 23 | $257,607 |
| ImbruvicaIbrutinib | 12 | $226,205 |
| CreonLipase/Protease/Amylase | 13 | $46,551 |
| Imatinib Mesylate | 27 | $29,066 |
| EliquisApixaban | 40 | $26,026 |
| Hydroxyurea | 28 | $866 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 24 | $803 |
| Ondansetron Hcl | 34 | $683 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 24 | $602 |
| Gabapentin | 45 | $586 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 13 | $387 |
| Mirtazapine | 34 | $347 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisTasigna | $291 | $361,55616 claims |
| GSKOjjaara | $84 | $271,21011 claims |
| Beigene USA, Inc.Brukinsa | $544 | $257,60723 claims |
| AbbVieCreon | $129 | $46,55113 claims |
| PfizerEliquis | $323 | $26,02640 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 507 medical oncology providers in Florida.
Other medical oncology in Delray Beach
- Warren BrennerDelray Beach$99K
- Neil LoveMiami$5.6M
- Mahdi TahaBoca Raton$1.7M
- Raji ShameemOrlando$1.3M
- Mohammad JahanzebBoca Raton$1.3M
- Michel VelezOrlando$927K
- Yuanbin ChenOrlando$810K
- Reshma MahtaniPlantation$608K
- Rebecca MorooseOrlando$543K
- Yasser KhaledOrlando$444K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.